Biomaterials to study tolerance immune induction kinetics
研究耐受免疫诱导动力学的生物材料
基本信息
- 批准号:10458635
- 负责人:
- 金额:$ 37.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-14 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAcetalsAcidsAddressAdoptive TransferAffectAftercareAmericanAnimal ModelAnti-Inflammatory AgentsAntibodiesAntigen PresentationAntigen-Presenting CellsAntigensAutoimmuneAutoimmune DiseasesBiocompatible MaterialsBiological ModelsC57BL/6 MouseCD80 geneCardiotoxicityCell CommunicationCell physiologyCellsClinicalCohort EffectCommunicationDataDelayed HypersensitivityDendritic CellsDevelopmentDexamethasoneDextransDiseaseDoseEncapsulatedEngineeringEvaluationExperimental Autoimmune EncephalomyelitisExperimental ModelsFOXP3 geneFormulationGenerationsGlycolatesGoalsHepatotoxicityHourIL2RA geneITGAM geneITGAX geneImmuneImmune ToleranceImmunologicsImmunologistImmunosuppressionIn VitroInfectionInflammationInterferon Type IIInterferonsInterleukin-10KineticsLipopolysaccharidesMajor Histocompatibility ComplexMalignant NeoplasmsMeasuresMediatingMethodsModelingMolecular Sieve ChromatographyMultiple SclerosisMusMyelin Basic ProteinsOnset of illnessOvalbuminParticle SizeParticulatePathogenesisPeptidesPeriodicityPhagocytesPhagolysosomePhagosomesPharmaceutical PreparationsPolyestersPolymersProteinsProteolipidsPublishingReadingRegulatory T-LymphocyteRelapseResearchResearch PersonnelRiskRoleSignal TransductionSirolimusSpleenSplenocyteSystemT cell responseT-LymphocyteT-Lymphocyte SubsetsTechnologyTimeTransforming Growth FactorsVaccinesWorkattenuationbiodegradable polymercentral nervous system demyelinating disorderclinically relevantcytokinedesigneffector T cellexperimental studyimmunological synapsein vivomacrophagemouse modelmultiple sclerosis treatmentnanonanoparticleoligodendrocyte-myelin glycoproteinparticleresponseside effect
项目摘要
ABSTRACT
We plan to explore the kinetics of the immune synapse, as it relates to generation of tolerance, using
nano/microparticles (Ps) fabricated from the polymer acetalated dextran (Ac-DEX). Previously, we have shown
attenuation of clinical score with treatment of Ac-DEX particles encapsulating myelin basic protein (MBP) and
dexamethasone (DXM), using a C57Bl/6 mouse model of experimental autoimmune encephalomyelitis (EAE).
We continued this research and illustrated that Ac-DEX particles encapsulating proteolipid protein (PLP) and
rapamycin (Rapa) in a SJL relapse and remitting model of EAE completely reduced clinical score to baseline
when given after disease onset. The degree of reduction of clinical score for both of these EAE models was
greater for the Ac-DEX particles systems than observed in other published antigen-specific EAE treatments that
used particle systems. Our particle system is unique because it relies on the highly tunable polymer Ac-DEX.
Ac-DEX is ideal for delivery of agents to phagocytic cells because it is acid-sensitive and has significantly
increased degradation in the low acid (~pH 5) of the phagosome. In addition to this it has tunable degradation
rates that can range from hours to months, which is a unique range from commonly used polyesters (e.g.
poly(lactic-co-glycolic acid) (PLGA)) that have degradation on the order of months. Moreover, Ac-DEX is unique
from polyesters because its degradation products are pH neutral, and do not have the potential to shift the local
pH or damage sensitive payloads. We have shown that Ac-DEX particles have degradation rates that affect both
antibody and cellular response for traditional vaccine and hypothesize similar effects for generation of tolerance.
Therefore, we hypothesize that Ac-DEX particles promote antigen specific immune tolerance by inducing Tregs
and that the cyclic acetal coverage of Ac-DEX impact degradation rate and modulate the immune synapse. We
have three specific aims to address this hypothesis. Aim 1 is focused on formulation of the polymer and particles.
Both a MS representative antigen as well as the model antigen OVA will be encapsulated. Particle parameters
like size and loading will be determined. Ac-DEX polymer with various cyclic acetal coverages will be fabricated
to degrade over a broad range of times. Aim 2 focuses on in vitro and in vivo studies to understand the immune
synapse and how that relates to particle degradation times. The metrics for evaluation will be generation of
inducible T-regulatory cells (iTregs). Furthermore, we will optimize systems using a delayed type hypersensitivity
(DTH) model of inflammation. The relationship between particle degradation and generation of tolerance will be
optimized. In Aim 3, the optimized formulation will be evaluated in a model of MS and expression of Tregs, as well
as other immunological characterizations will be carried out. The overall goal of this work is to evaluate the Ac-
DEX particles systems as an antigen-specific treatment for MS and to understand the influence of release of
tolerance agents (e.g. antigen and Rapa) on the generation of antigen specific immune tolerance.
摘要
我们计划探索免疫突触的动力学,因为它与耐受的产生有关,使用
由聚合物缩醛葡聚糖(Ac-DEX)制备的纳米/微米粒子(Ps)。之前,我们已经展示了
Ac-DEX颗粒包裹髓鞘碱性蛋白(MBP)治疗对临床评分的影响
地塞米松(DXM),使用C57BL/6小鼠实验性自身免疫性脑脊髓炎(EAE)模型。
我们继续这项研究,并说明了Ac-DEX颗粒包裹蛋白质脂蛋白(PLP)和
雷帕霉素在SJL复发和缓解的EAE模型中完全降低临床评分至基线
在疾病发作后给药。这两种EAE模型的临床评分降低的程度都是
与其他已发表的抗原特异性EAE治疗方法相比,Ac-DEX颗粒系统的作用更大
已使用粒子系统。我们的粒子系统是独一无二的,因为它依赖于高度可调的聚合物Ac-DEX。
AC-DEX是将药物输送到吞噬细胞的理想药物,因为它对酸敏感,并且具有显著的
吞噬小体在低酸度(~pH 5)时降解增加。除此之外,它还具有可调的降级
价格从几小时到几个月不等,这是与常用聚酯(例如
聚乳酸-羟基乙酸(PLGA))的降解率约为几个月。此外,Ac-DEX是独一无二的
来自聚酯,因为它的降解产物是pH中性的,并且不会改变局部
PH值或对损坏敏感的有效载荷。我们已经证明了AC-DEX粒子的降解率对两者都有影响
传统疫苗的抗体和细胞反应,并假设产生耐受性的效果相似。
因此,我们假设Ac-DEX颗粒通过诱导Treg来促进抗原特异性免疫耐受。
Ac-DEX的环缩醛覆盖影响降解速率,调节免疫突触。我们
有三个具体的目标来解决这个假设。目标1集中在聚合物和颗粒的配方上。
MS代表抗原和模型抗原OVA都将被包裹。粒子参数
类似的大小和装载量将被确定。将制造具有不同环缩醛覆盖度的AC-DEX聚合物
在广泛的时间范围内降解。目的2着重于体外和体内研究,以了解免疫
突触以及它与颗粒降解时间的关系。评估的指标将是
可诱导T调节细胞(ITregs)。此外,我们将使用延迟型超敏反应来优化系统
(DTH)炎症模型。颗粒降解和公差的产生之间的关系将是
最优化。在目标3中,将在MS和Tregs表达的模型中对优化的配方进行评估
还将进行其他免疫学鉴定。这项工作的总体目标是对Ac-Ac进行评估。
地塞米松颗粒系统作为抗原特异性治疗多发性硬化症并了解其释放的影响
耐受剂(如抗原和RAPA)对抗原特异性免疫耐受的产生。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kristy M Ainslie其他文献
Kristy M Ainslie的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kristy M Ainslie', 18)}}的其他基金
Mechanistic evaluation of mast cell agonists combined with TLR, NOD and STING agonists.
肥大细胞激动剂联合 TLR、NOD 和 STING 激动剂的机制评估。
- 批准号:
10657847 - 财政年份:2023
- 资助金额:
$ 37.66万 - 项目类别:
Diversity Supplement - Formulation to Generate Tolerance Towards Type 1 Diabetes
多样性补充剂 - 产生对 1 型糖尿病耐受性的配方
- 批准号:
10560761 - 财政年份:2021
- 资助金额:
$ 37.66万 - 项目类别:
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
可调节的时间药物释放,用于优化胶质母细胞瘤的协同联合治疗
- 批准号:
10449370 - 财政年份:2021
- 资助金额:
$ 37.66万 - 项目类别:
Formulation to Generate Tolerance Towards Type 1 Diabetes
产生对 1 型糖尿病耐受性的配方
- 批准号:
10436981 - 财政年份:2021
- 资助金额:
$ 37.66万 - 项目类别:
Formulation to Generate Tolerance Towards Type 1 Diabetes
产生对 1 型糖尿病耐受性的配方
- 批准号:
10713401 - 财政年份:2021
- 资助金额:
$ 37.66万 - 项目类别:
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
可调节的时间药物释放,用于优化胶质母细胞瘤的协同联合治疗
- 批准号:
10675073 - 财政年份:2021
- 资助金额:
$ 37.66万 - 项目类别:
Formulation to Generate Tolerance Towards Type 1 Diabetes
产生对 1 型糖尿病耐受性的配方
- 批准号:
10310642 - 财政年份:2021
- 资助金额:
$ 37.66万 - 项目类别:
Formulation to Generate Tolerance Towards Type 1 Diabetes
产生对 1 型糖尿病耐受性的配方
- 批准号:
10615119 - 财政年份:2021
- 资助金额:
$ 37.66万 - 项目类别:
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
可调节的时间药物释放,用于优化胶质母细胞瘤的协同联合治疗
- 批准号:
10309049 - 财政年份:2021
- 资助金额:
$ 37.66万 - 项目类别:
Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine
优化通用流感亚单位纳米/微粒疫苗
- 批准号:
10328236 - 财政年份:2020
- 资助金额:
$ 37.66万 - 项目类别:
相似海外基金
RUI: Development of Bench-stable N-quaternized ketene N,O-acetals as Multifunctional Reagents for Organic Synthesis
RUI:开发实验室稳定的 N-季铵化乙烯酮 N,O-缩醛作为有机合成多功能试剂
- 批准号:
2155127 - 财政年份:2022
- 资助金额:
$ 37.66万 - 项目类别:
Standard Grant
SusChEM: Pro-Active Networks from Degradable Acetals (PANDAs) via Thiol-ene Photopolymerization
SusChEM:通过硫醇烯光聚合从可降解乙缩醛 (PANDA) 形成主动网络
- 批准号:
1710589 - 财政年份:2017
- 资助金额:
$ 37.66万 - 项目类别:
Standard Grant
CAREER: SusChEM: New organocatalytic approaches to the stereo- and regioselective construction of acetals
职业:SusChEM:缩醛立体和区域选择性构建的新有机催化方法
- 批准号:
1350060 - 财政年份:2014
- 资助金额:
$ 37.66万 - 项目类别:
Continuing Grant
Development of novel reactivitity of methylene acetals and its application to synthesis of heterocycles
亚甲基缩醛新反应活性的发展及其在杂环合成中的应用
- 批准号:
26460023 - 财政年份:2014
- 资助金额:
$ 37.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Metal-Catalyzed Cross Coupling with N,O-Acetals and Acetals
N,O-缩醛和缩醛的金属催化交叉偶联
- 批准号:
8580437 - 财政年份:2013
- 资助金额:
$ 37.66万 - 项目类别:
Metal-Catalyzed Cross Coupling with N,O-Acetals and Acetals
N,O-缩醛和缩醛的金属催化交叉偶联
- 批准号:
9035402 - 财政年份:2013
- 资助金额:
$ 37.66万 - 项目类别:
Metal-Catalyzed Cross Coupling with N,O-Acetals and Acetals
N,O-缩醛和缩醛的金属催化交叉偶联
- 批准号:
8822307 - 财政年份:2013
- 资助金额:
$ 37.66万 - 项目类别:
Metal-Catalyzed Cross Coupling with N,O-Acetals and Acetals
N,O-缩醛和缩醛的金属催化交叉偶联
- 批准号:
8690110 - 财政年份:2013
- 资助金额:
$ 37.66万 - 项目类别:
Geminal acylation with nitrogen-bearing acetals
用含氮缩醛进行双子酰化
- 批准号:
414686-2011 - 财政年份:2011
- 资助金额:
$ 37.66万 - 项目类别:
University Undergraduate Student Research Awards
RUI: Synthesis of Unnatural Amino Acids using Fmoc-protected N,O-Acetals
RUI:使用 Fmoc 保护的 N,O-缩醛合成非天然氨基酸
- 批准号:
0957618 - 财政年份:2010
- 资助金额:
$ 37.66万 - 项目类别:
Standard Grant